
2cureX Investor Relations Material
Latest events

Investor Update
2cureX
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from 2cureX
Access all reports
2cureX AB is a medtech company focused on improving cancer treatment through functional drug sensitivity testing. Its flagship product, IndiTreat, is an in vitro diagnostic (IVD) test that helps predict a cancer patient’s response to different drugs, enabling personalized treatment plans. IndiTreat is designed to assist in treating colorectal, ovarian, and pancreatic cancers, among others. The company is headuqartered in Copenhagen, Denmark, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
2CUREX
Country
🇸🇪 Sweden